Alkermes (ALKS) Leaped To A 9-Month High On Phase 3 Study Results

Alkermes (ALKS) announced after the bell Thursday that its Phase 3 study of ALKS 5461 met its primary endpoint. The drug showed significantly reduced symptoms of depression in patients with major depressive disorder.

from RTT - Before the Bell http://ift.tt/2e3fdfs
via IFTTT